Nelson Bryce J B, Andersson Jan D, Wuest Frank
Department of Oncology, University of Alberta, 11560 University Ave, Edmonton, AB T6G 1Z2, Canada.
Edmonton Radiopharmaceutical Center, Alberta Health Services, 11560 University Ave, Edmonton, AB T6G 1Z2, Canada.
Pharmaceutics. 2020 Dec 31;13(1):49. doi: 10.3390/pharmaceutics13010049.
This review outlines the accomplishments and potential developments of targeted alpha (α) particle therapy (TAT). It discusses the therapeutic advantages of the short and highly ionizing path of α-particle emissions; the ability of TAT to complement and provide superior efficacy over existing forms of radiotherapy; the physical decay properties and radiochemistry of common α-emitters, including Ac, Bi, Ra, Pb, Th, Ra, At, and Tb; the production techniques and proper handling of α-emitters in a radiopharmacy; recent preclinical developments; ongoing and completed clinical trials; and an outlook on the future of TAT.
本综述概述了靶向α粒子疗法(TAT)的成就和潜在发展。它讨论了α粒子发射的短且高电离路径的治疗优势;TAT补充现有放射治疗形式并提供更高疗效的能力;常见α发射体(包括锕、铋、镭、铅、钍、镭、砹和铽)的物理衰变特性和放射化学;放射性药物中α发射体的生产技术和正确处理;最近的临床前进展;正在进行和已完成的临床试验;以及TAT的未来展望。